Tag: Saluda Medical

Saluda Medical announces presentation of 36-month EVOKE trial data at NANS...

Saluda Medical has announced that late-breaking data from the "landmark" EVOKE clinical trial was presented at the recent North American Neuromodulation Society (NANS) annual...

Saluda Medical initiates US commercialisation of the Evoke spinal cord stimulation...

Saluda Medical has announced plans for a limited commercial release of its Evoke spinal cord stimulation (SCS) system in the USA, with a full commercial...

Saluda Medical presents data on 24-month holistic response to spinal cord...

Saluda Medical has announced that Steven Falowski (Argires-Marotti Neurosurgical Associates of Lancaster, Lancaster, USA) recently presented late-breaking 24-month data from the company’s EVOKE study at...

Saluda Medical raises US$125m to boost Evoke spinal cord stimulation offering

Saluda Medical has finalised US$125 million in equity financing, with the proceeds being used in part to operationalise and scale commercialisation of the company’s Evoke spinal...

Saluda Medical receives FDA approval for the Evoke spinal cord stimulation...

Saluda Medical has announced that it has received full approval from the US Food and Drug Administration (FDA) for the Evoke spinal cord stimulation (SCS)...